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ABSTRACT
Background: Warfarin has been the oral anticoagulant of choice for the treatment of 
thromboembolic disease. However, upwards of 50% of all new anticoagulant 
prescriptions are now for direct oral anticoagulants (DOAC). Despite this, outcome data 
evaluating preinjury anticoagulants remains scarce following traumatic brain injury 
(TBI). Our study objective is to determine the effects of preinjury anticoagulation on 
outcomes in older adults with TBI.  
Methods: Patient data was obtained from 29 level 1 and 2 trauma centers from 2012 to 
June 30, 2018. Overall, 8312 patients who were aged65 years  or older, suffering a 
ground level fall, and with an Abbreviated Injury Scale score (AIS)-head of ≥ 3 were 
identified. Patients were excluded if they presented with no signs of life or a traumatic 
mechanism besides ground level fall. Statistical comparisons were made using 
multivariable analyses with anticoagulant/antiplatelet use as the independent variable.
Results: Of the total patients with TBI, 3293 were on antiplatelet agents (AP), 669 on 
warfarin, 414 on warfarin + AP, 188 on DOACs, 116 on DOAC + AP, and 3632 on no 
anticoagulant. There were 185 (27.7%) patients on warfarin and 43 (22.9%) on a DOAC 
with a combined outcome of mortality or hospice  as compared to 575 (15.8%) in the no 
anticoagulant group (p<0.001). After adjusting for patient factors, there was an increased 
risk of mortality or hospice in the warfarin (OR 1.60; 95% CI 1.27 – 2.01) and DOAC 
group (OR 1.67; 95% CI 1.07 – 2.59) as compared to no anticoagulant. Warfarin+AP was 
associated with an increased risk of mortality or hospice (OR 1.61; 95% CI 1.18-2.21) 
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Conclusions: In older adults with TBI, preinjury treatment with warfarin or DOACs 
resulted in an increased risk of mortality or hospice whereas preinjury AP therapy did not 
increase risk. Future studies are needed with larger sample sizes to directly compare TBI 
outcomes associated with preinjury warfarin versus DOAC use. 
Keywords: Traumatic brain injury, Anticoagulants, Antiplatelet agents, Factor Xa 
Inhibitors, Warfarin 
INTRODUCTION
Older adults account for upwards of 30% of all trauma admissions and 50% of all 
trauma-related deaths in the United States.1 Traumatic brain injury (TBI) is one of the 
most common injuries occurring in older adults as well as one of the most fatal.1-2 
Although 75% of TBIs are classified as mild, more severe TBIs can be devastating 
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patient's life.3 Patients with advanced age also frequently present with significant 
preinjury comorbidities and prescription medication treatments that often exacerbate their 
traumatic injuries and impact subsequent recovery. As the population has continued to 
age and life expectancy is increasing, the median age of traumatic admissions has 
increased from 56 to 65 years old since the year 2000.4 Increasing life expectancy is also 
leading to a rise in the indications for anticoagulation therapy, such as atrial fibrillation 
(AF) and venous thromboembolism (VTE), which can greatly complicate the care of the 
older adult trauma patient.5,6 
Anticoagulant medications are used for the prevention of stroke in AF as well as 
the treatment and prevention of VTE. Historically, the vitamin K antagonist warfarin has 
been the anticoagulant of choice due to its established efficacy, ease of laboratory 
monitoring, and availability of reversal agents. Despite the availability of effective 
reversal agents like vitamin K, fresh frozen plasma (FFP), and prothrombin complex 
concentrate (PCC), it is well established that preinjury warfarin usage leads to increased 
morbidity and mortality following TBI.7-9 In a prior study involving all types of traumatic 
injury, we found that preinjury antiplatelet and/or warfarin use was associated with an 
increased risk of mortality.10 However, preinjury direct oral anticoagulant (DOAC) use 
was not associated with a statistically increased risk of adverse outcomes.
The DOACs apixaban, rivaroxaban, dabigatran, and edoxaban work by inhibiting 
specific clotting factors and are noted to have increased patient compliance and 
satisfaction as compared to warfarin.11-12 The DOACs have also been shown to have 
superior safety profiles for spontaneous bleeding as compared to warfarin. These facts 
have led to a dramatic increase in prescribing of these agents in recent years.13-18 Despite 
the clear advantages of DOACs there are also drawbacks such as no commercially 
available laboratory assays for monitoring drug levels, costly reversal agents, and 
conflicting results on outcomes following traumatic injury; all of which have limited even 
more widespread use of these agents.19-22
This study was performed using data from a collaborative quality initiative, the 
Michigan Trauma Quality Improvement Program (MTQIP). Our objective was to 
determine the effects on mortality and hospital complications of preinjury anticoagulation 
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hypothesized that older adults with TBI on preinjury DOAC agents would have increased 
rates of mortality, resource utilization, and serious complications when compared to 
warfarin or antiplatelet therapy. 
METHODS
Data Collection
MTQIP consists of 29 American College of Surgeons Committee on Trauma 
verified level 1 and 2 trauma centers in Michigan. Data collection uses the existing 
trauma registry with standardized addition of MTQIP specific data elements at all 
participating hospitals.23 MTQIP utilizes a data definitions dictionary, based upon the 
National Trauma Data Standard with data being transmitted to the coordinating center at 
four-month intervals. Data extractors from all participating trauma centers are graded 
annually on data accuracy and inter-rater reliability. Supplementary data on preinjury 
anticoagulant and antiplatelet medication usage has been collected since January 2012. 
The inclusion criteria for MTQIP are as follows: at least one valid trauma code on 
admission; calculated Injury Severity Score (ISS) ≥ 5; and Emergency Department (ED) 
and hospital discharge disposition must be known. Additionally, patients were included 
in this study if they suffered a ground level fall, were ≥ 65 years old, and had TBI as 
defined by an Abbreviated Injury Scale (AIS) head score of ≥ 3. Excluded patients are 
those with no signs of life at initial evaluation (ED Systolic Blood Pressure = 0, Pulse = 
0, Glasgow Coma Scale = 3) or a traumatic mechanism other than ground level fall.24 
Patients were also excluded for potential coding errors where more than one 
anticoagulant was present upon admission. All ISS values were derived from registrar 
abstracted AIS 2005 codes with 2008 updates. 
This study was submitted to the St. Joseph Mercy Ann Arbor Institutional Review 
Board and given a determination of “not regulated” due to the de-identified status of 
patients in the database.  
Analysis
Data was extracted from the MTQIP database and the study cohort consists of 
patients admitted between January 1, 2012 and June 30, 2018. For all outcomes, 
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Patients in the antiplatelet group were taking an antiplatelet agent alone with no 
anticoagulant medication prescribed. Antiplatelet agents included aspirin and P2Y12 
inhibitors such as clopidogrel, ticagrelor, and prasugrel.
Univariate differences in patient characteristics were evaluated using Chi-squared 
tests for categorical variables and analysis of variance F-tests for continuous variables.  
Outcomes of interest included a combined end point of mortality or hospice, serious 
complications, and resource utilization. Serious complications is a composite outcome 
which includes grade 2 and 3 morbidity events associated with increased mortality or 
utilization of resources: decubitus ulcer, deep vein thrombosis (DVT), enterocutaneous 
fistula, extremity compartment syndrome, pneumonia, PE, unplanned intubation, 
unplanned return to the operation room, adult respiratory distress syndrome, acute kidney 
injury requiring dialysis, cardiac arrest, myocardial infarction, severe sepsis, or 
stroke.23,25 Resource utilization measures investigated were need for surgery during 
admission, transfusion with fresh frozen plasma (FFP) in the first 4 hours after arrival, 
transfusion with platelets in the first 4 hours after arrival, hospital length of stay (LOS), 
or intensive care unit (ICU) LOS. When calculating the mean number of transfusions, 
patients who did not receive transfusions were excluded. 
Statistical comparisons were made using multivariable analyses for the outcome 
of interest with anticoagulant/antiplatelet use as the independent variable, and using no 
anticoagulant/antiplatelet as the reference category. Two-stage multivariable logistic 
regression modeling was used to account for differences in patient characteristics to allow 
for risk adjustment for the various anticoagulation and antiplatelet cohorts (Supplement). 
Odds ratios (OR) as well as confidence intervals (CI) were reported for all outcomes of 
interest based on adjustment for patient-specific factors. 
To account for patient differences, a two-stage modeling approach was used. In 
the first stage, patient ‘risk scores’ were created by using regression (logistic regression 
for binary outcomes, linear regression for continuous outcomes) to model the outcome of 
interest, including patient case-mix factors, injury severity, time trend (year), and trauma 
center level as covariates. Characteristics that were not constantly related to the outcome 
throughout all values of the variable were entered into models as categories instead of 
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score >2 in the extremity, chest, and abdominal regions were included in models. In a few 
instances there were missing values for covariates. To minimize bias, these values were 
accounted for using a category for missingness. From the first-stage models, patient-level 
linear predictions (‘risk scores’) were obtained. In second-stage logistic regression 
models, each outcome of interest was modeled using patient-level risk scores as a 
covariate and including anticoagulant/antiplatelet use as our independent variable. 
Additionally, to account for within-hospital clustering, cluster-robust standard errors 
were used.
Statistical Methods
Statistical analyses was performed by a biostatistician using Stata 15.0 
(StataCorp, College Station, TX). Statistical significance was defined as a p-value < 0.05. 
Average values are expressed as the mean ± standard deviation (SD).
RESULTS
Study Population
Overall, 8312 older adults aged 65 years or older were admitted to participating 
MTQIP hospitals with a TBI after a ground level fall during the study (Figure 1). There 
were 1387 (16.7%) patients on a preinjury anticoagulant, of which 304 (3.7%) were on a 
DOAC and 1083 (13.0%) on warfarin. 3293 (39.6%) patients were on an antiplatelet 
agent alone, and 3632 (43.7%) patients were on no preinjury anticoagulation or 
antiplatelet medication (no anticoagulant). Of the 304 patients in the DOAC group, 116 
(38.2%) were taking a concomitant antiplatelet agent; 414 (38.2%) patients in the 
warfarin group were taking a concomitant antiplatelet agent. The majority of patients 
taking DOACs were receiving factor Xa inhibitors (n=259, 85.2%) as opposed to direct 
thrombin inhibitors (n=45, 14.8%). 
Anticoagulated patients tended to be male, insured, and had more preinjury 
congestive heart failure, diabetes, and hypertension (Table 1). Patients taking preinjury 
warfarin, as compared to DOAC, were more likely to have an ISS ≥ 25 (33.0% vs. 
25.5%; p<0.001) as well an AIS head score ≥ 4 (62.7% vs. 51.6%; p<0.001), 
respectively. Patients in the preinjury DOAC group were more likely to present with an 
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(15.5% vs. 10.6%; p<0.05). Overall, there were 944 (11.4%) patients in the study with a 
preadmission DNR and among this group 591 (62.6%) survived to hospital discharge. 
Anticoagulant Outcomes
Patients in the no anticoagulant group had a rate of combined mortality or hospice 
of 15.8% (n=575). The DOAC alone group had 43 patients (22.9%) with a combined 
outcome of mortality or hospice, as compared to the warfarin alone group with 185 
patients (27.7%); p<0.001 (Figure 2). After adjusting for patient factors, preinjury 
warfarin (OR 1.60; 95% CI 1.27-2.01) and DOACs (OR 1.67; 95% CI 1.07-2.59) were 
significantly associated with combined mortality or hospice when compared to the no 
anticoagulant group. Mortality or hospice was also stratified by preinjury agents and head 
AIS score, as seen in Table 2. Within the DOAC alone group, there was no significant 
difference between direct thrombin inhibitors (OR 1.16; 95% CI 0.37-3.64) or factor Xa 
inhibitors (OR 1.38; 95% CI 0.94-2.01) with regard to combined mortality or hospice 
when compared to patients on no anticoagulant.  
Serious complications occurred in 11.8% of patients taking warfarin alone (OR 
1.32; 95% CI 0.94-1.85) and to 6.9% of patients taking DOACs alone (OR 1.15; 95% CI 
0.69-1.92) as compared to no anticoagulant (Table 3). There was no difference in the 
need for surgery between the warfarin and DOAC alone groups (warfarin OR 0.79; 95% 
CI 0.60-1.04; DOAC OR 1.31; 95% CI 0.73-2.36). However, patients on warfarin 
alonewere significantly more likely to receive FFP infusions (OR 9.48; 95% CI 5.37-
16.70) compared to patients on no anticoagulant, whereas patients taking DOACs alone 
(OR 1.06; 95% CI 0.30-3.77) were not. Warfarin alone patients received an average of 
2.3 units of FFP transfusions for anticoagulation reversal. Preinjury warfarin therapy was 
also associated with a longer hospital LOS as compared to DOACs (6.7 days vs. 5.2 days, 
p<0.001, respectively). After risk adjustment, patients taking warfarin alone as compared 
to no anticoagulant were expected to have a significantly longer LOS (+0.43 days, 95% 
CI 0.09 to 0.78 days); although the expected difference in LOS for patients taking 
DOACs compared to no anticoagulant was longer, the results were not significantly 
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The antiplatelet group had 564 (17.1%) patients with an outcome of combined 
mortality or hospice as compared to 15.8% in the no anticoagulation group. After 
adjusting, there was no significant increased risk of combined mortality or hospice in the 
antiplatelet group as compared to patients on no anticoagulant (OR 1.13; 95% CI 0.94-
1.36). There were 113 (27.3%) patients taking preinjury warfarin with an antiplatelet 
agent with the outcome of mortality or hospice and after adjustment this remained 
significantly increased as compared to no anticoagulation (OR 1.61; 95% CI 1.18-2.21). 
Patients taking a DOAC with an antiplatelet agent had a 19.0% rate of combined 
mortality or hospice, which was not significantly higher than no anticoagulation (OR 
0.93; 95% CI 0.46-1.87). 
Preinjury antiplatelet agents alone were associated with an increased risk of 
serious complications (OR 1.30; 95% CI 1.07-1.58), but were not associated with an 
increased need for a surgery (OR 0.89; 95% CI 0.71-1.12). Platelet transfusions for 
reversal were common in the antiplatelet alone group (OR 4.11; 95% CI 2.45-6.88) 
compared to the no anticoagulant group. 
DISCUSSION
This large multi-center study of 8312 older adults from the MTQIP database 
evaluated outcomes following TBI in older adults with preinjury use of anticoagulant 
and/or antiplatelet agents. Preinjury warfarin use, as compared to no anticoagulant, was 
associated with a significant increase in mortality or discharge to hospice, serious in-
hospital complications, and longer hospital LOS. Despite having the same mechanism of 
injury and age profile as the no anticoagulant patients, the preinjury warfarin cohort had 
significantly worse head injuries as evidenced by higher AIS head scores, lower 
admission GCS score, and more patients requiring ventilator support. This result is 
similar to and confirms the results found in previous evaluations of preinjury warfarin 
use.22,26
DOAC use was also found to increase mortality or hospice in the adjusted 
analysis as compared to the no anticoagulation group. When compared directly to 
warfarin in the unadjusted analysis there was a statistically lower rate of mortality or 
hospice in the DOAC group. Unfortunately, sample sizes in our analysis were too small 
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previous studies of trauma patients have yielded similar results. A study of 162 patients 
on preinjury anticoagulant therapy with blunt traumatic injuries and an AIS head score of 
< 4 found a significantly lower mortality in patients taking DOACs (4.9%) as compared 
to warfarin (20.8%).27 Similiarly, a study looking at 186 older adults with TBI on 
preinjury anticoagulants and found an increased in-hospital mortality with warfarin as 
compared to DOACs despite adequate reversal agent administration in the warfarin 
group.28 Our study, as well as those previously reported, should serve as hypothesis 
generating for a larger analysis directly comparing preinjury warfarin to DOAC. 
The finding that preinjury warfarin and DOAC use yielded similar hospital 
outcomes following TBI when compared to patients taking no anticoagulation or 
antiplatelet agents, is especially interesting given the lack of dedicated reversal agent for 
DOACs during our study period. Both idarucizumab and andexanet alfa were not 
available during the entirety of our study period so this data was unable to be included. 
PCC products have been recommended in national guidelines as a potential hemostatic 
agent for DOACs with small human studies showing variable efficacy.29-32 
This study of preinjury DOACs represents data from before commercially 
available reversal agents such as andexanet alfa.33 One hypothesis for preinjury DOAC 
outcomes not appearing worse than warfarin despite the lack of specific reversal agents 
could be that patients were receiving only a partial or minimal reversal with PCC agents. 
Studies of severe TBI have found that the coagulation cascade is dramatically altered due 
to large release of tissue factor and other micro particles.34 It is possible that residual 
DOAC inhibition of the clotting cascade after partial reversal may help reverse early 
hypercoagulability in TBI. Future studies are needed to determine the clinical outcomes 
of patients with TBI taking preinjury DOAC reversed with idarucizumab and andexanet 
alfa. Previous studies have also suggested that preinjury warfarin use is a significant risk 
factor for delayed new or worsening hemorrhage which could also be responsible for the 
results found in this study.35 It is unknown based on the current literature whether this 
same risk applies to preinjury DOACs. 
Due to the lack of an available DOAC reversal agent until recently, it is possible 
that there could be a prescribing bias in outpatients to use warfarin in individuals deemed 
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in an observational study, we attempted to control for baseline comorbidities. 
Functionally dependent health status upon admission was also used a surrogate for frailty 
and was more prevalent in the DOAC population than warfarin. Pre-admission DNR was 
also recorded, with the DOAC population having a higher prevalence than warfarin. 
Patients who were anticoagulated were much more likely to have a history of stroke, 
COPD, and hypertension than patients not on a preinjury anticoagulant. This difference is 
unavoidable in an observational study, which emphasized the need for our use of a robust 
multivariate regression analysis. 
Patients presenting with a TBI on antiplatelet agents were also found to have 
similar outcomes to patients taking no anticoagulants prior to injury. To our knowledge, 
this study of 3293 TBI patients taking preinjury antiplatelet agents is the largest analysis 
of its kind in TBI patients and expands upon the results of previous literature. A 
retrospective study of 364 patients with TBI on antiplatelet agents by Sumiyoshi and 
colleagues found on univariate analysis a significant association with in-hospital 
mortality. However, once entered into multivariate analysis this effect was not present.36 
Another large retrospective analysis at a single center of 1051 patients on antiplatelet 
agents found no difference in hospital outcomes whether single or dual antiplatelet 
therapy was used preinjury in elderly TBI patients.8 Although a significant limitation is 
that information is not available on outcomes for specific antiplatelet agents, the results 
of our study appear to confirm that preinjury antiplatelet agents as a whole do not worsen 
outcomes following TBI.
To help isolate the effects of head injuries and minimize mortality associated with 
injuries to other organ systems, patients were included in this analysis if their mechanism 
of injury was a low-level fall. Very few patients presented with an AIS score >2 in any 
organ system besides head, so all morbidity and mortality seen can likely be attributed to 
the TBI. We also aimed to consider pre-admission DNR as a contributing factor, 
especially since this study was evaluating mortality in a geriatric population. DNR status 
was not included in the risk adjustment, despite it being an important consideration, 
because extensive data validation performed within MTQIP has discovered that there is 
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The primary limitation of this study is its observational design. However, the 
nature of the study question is not conducive to a prospective study where patients are 
randomized prior to a traumatic injury. MTQIP is a large multicenter registry with 
prospectively collected data that is submitted with frequent audits making it a high 
quality of evidence. Although the statistical analysis was designed with small sample 
sizes in mind, it remains a limitation that there may not have been enough patients in the 
anticoagulant groups to answer the study question definitively. There was also a disparity 
in the number of patients who presented on preinjury warfarin as compared to DOACs. It 
is likely that there are important factors at play that influenced prescribing patterns that 
are unable to be discerned by this analysis. For example, more patients in the preinjury 
DOAC group presented with a DNR order, which could be a surrogate for greater health 
literacy. It is possible that there are differences between these two groups in access to 
care, high risk clinical features, or other important variables that favor one type of 
anticoagulant over the other. 
Another significant limitation of this study is the absence of coagulation 
laboratory tests upon admission and reversal agents administered. MTQIP began 
mandatory reporting of this data in January 2018 which made it unavailable for a 
significant time period within our study. Degree of anticoagulation as well as reversal has 
been shown previously to predict adverse outcomes with preinjury warfarin.37,38 A study 
by Pieracci and colleagues looking at 40 patients on preinjury warfarin, including 22 
within the therapeutic range, found that overall mortality was increased in the therapeutic 
warfarin group as compared to patients taking warfarin with subtherapeutic International 
Normalized Ratio (INR) levels.39 There have also been previous studies that have found 
conflicting results of preinjury warfarin not having any significant effects on outcomes 
following head injuries.40,41 The availability of INR values for our present study would 
have helped to shed light on these conflicting results. 
Patient data was collected from level 1 and 2 trauma centers from across the state 
of Michigan. Despite the heterogeneity of this design the results may not be applicable to 
other regions of the country or non-designated trauma centers. Another significant 
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CONCLUSION
Older adult patients aged 65 years or greater presenting with a TBI on preinjury 
warfarin were found to have an increase in mortality or hospice, serious complications, 
and use of hospital resources as compared to no anticoagulation. Preinjury DOAC agents, 
including factor Xa and direct thrombin inhibitors, also showed a higher rate of mortality 
or hospice and serious complications as compared to no anticoagulation. Future studies 
are needed with larger sample sizes to directly compare outcomes with preinjury warfarin 
directly to DOACs. 
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Table 1. Baseline Characteristics









     (N=116)
p
Age, years + SD   80.3 ± 8.7  81.1 ± 7.8      81.2 ± 7.4 81.2 ± 7.7  80.8 ± 6.9 <0.001
Female, No (%) 1919  (52.8) 314  (46.9)     143  (34.5)   99  (52.7)    49  (42.2) <0.001
Race, No (%)
   White
   Black
   Other
3156  (86.9)
  348  (9.6)
  128  (3.5)
616  (92.1)
  37  (5.5)
  16  (2.4)
    379  (91.5)
      29  (7.0)
        6  (1.4)
179  (95.2)
    8  (4.3)
    1  (0.5)
  107  (92.2)
      6  (5.2)
      3  (2.6)
<0.001
Uninsured, No (%)     80  (2.2)     9  (1.3)         4  (1.0)     2  (1.1)       0  (0.0) <0.001








  835  (23.0)




    4  (0.6)
    132  (31.9)
    137  (33.1)
    143  (34.5)
        2  (0.5)
  85  (45.2)
  55  (29.3)
  47  (25.0)
    1  (0.5)
    44  (37.9)
    35  (30.2)
    37  (31.9)
      0  (0.0)
<0.001




AIS >2, No (%)
1740  (47.9)
1140  (31.4)





    141  (34.1)
    134  (32.4)
    139  (33.6)
 
  91  (48.4)
  52  (27.7)
  45  (23.9)
    48  (41.4)
    36  (31.0)




















  156  (4.3)
    11  (0.3)
    97  (2.7)
  24  (3.6)
    2  (0.3)
  14  (2.1)
      10  (2.4)
        0  (0.0)
        4  (1.0)
    8  (4.3)
    1  (0.5)
    2  (1.1)
      3  (2.6)
      1  (0.9)
      4  (3.4)
   0.41
0.69
0.22






  372  (10.2)
  173  (4.8)
  382  (10.5)
490  (73.8)
  70  (10.5)
  39  (5.8)
  70  (10.5)
    309  (74.6)
      35  (8.5)
      29  (7.0)
      41  (9.9)
144  (76.6)
  17  (9.0)
    7  (3.7)
  20  (10.6)
    83  (71.6)
    12  (10.3)
      5  (4.3)









    93  (2.6)
3402  (93.7)
    54  (1.5)
3495  (96.2)
    51  (1.4) 
 22  (3.3)
620  (92.7)
    6  (0.9)
  
635  (94.9)
  11  (1.6)
 
      14  (3.4)
    384  (92.8)
        5  (1.2)
  
    399  (96.4)
        7  (1.7)
    6  (3.2)
170  (90.4)
    5  (2.7)
    
178  (94.7)
    2  (1.1)
 
      2  (1.7)
  175  (90.5)
      1  (0.9)
  106  (91.4)
      0  (0.0)
  0.048
  0.003




  Renal failure
  CHF
  Current smoker
  Dementia
  Diabetes
  Disseminated cancer
  FDHS
  History of MI
  Hypertension
  Liver disease 
  147  (4.0)
  348  (9.6)
    77  (2.1)
  183  (5.0)
  258  (7.1)
  843  (23.2)
  742  (20.4)
    49  (1.3)
  683  (18.8)
    39  (1.1)
2178  (60.0)
    37  (1.0)
  48  (7.2)
102  (15.2)
  22  (3.3)
100  (14.9)
  27  (4.0)
  99  (14.8) 
163  (24.4)
  14  (2.1)
150  (22.4)
    5  (0.7)
488  (72.9)
    3  (0.4)
      24  (5.8)
      60  (14.5)
      15  (3.6)
      81  (19.6)
      18  (4.3)
      67  (16.2)
    161  (38.9)
        5  (1.2)
      80  (19.3)
      21  (5.1)
    329  (79.5)
        4  (1.0)
  19  (10.1)
  21  (11.2)
    2  (1.1)
  21  (11.2)
    9  (4.8)
  47  (25.0)
  43  (22.9)
    2  (1.1)
  52  (27.7)
    0  (0.0)
135  (71.8)
    1  (0.5)
    13  (11.2)
    15  (12.9)
      4  (3.4)
    17  (14.7)
      4  (3.4)
    18  (15.5)
    33  (28.4)
      1  (0.9)
    39  (33.6)
      1  (0.9)
    94  (81.0)













Abbreviations: DOAC, direct oral anticoagulant; SD, standard deviation; OSH, outside hospital; ISS, injury severity 
score;AIS, abbreviated injury scale; GCS, Glasgow coma score; HR, Heart Rate; ED, emergency department; bpm, 
beats per minute; SBP, systolic blood pressure; CVA, cerebrovascular accident; COPD, chronic obstructive pulmonary 
disorder; CHF, congestive heart failure; FDHS, functionally dependent health status; MI, myocardial infarction.                                                                                                               
Abbreviations: No AC, No anticoagulant; DOAC, direct oral anticoagulant; SD, standard deviation; OSH, outside 
hospital; AIS, abbreviated injury scale; GCS, Glasgow coma score; ED, emergency department; bpm, beats per minute; 
BP, blood pressure; CVA, cerebrovascular accident; COPD, chronic obstructive pulmonary disorder; CHF, congestive 
heart failure; FDHS, functionally dependent health status; MI, myocardial infarction.                                                                                                               
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* Calculated using Pearsons Chi-Squared test
Abbreviations: AIS, abbreviated injury score; DOAC, direct oral anticoagulant
AIS  Head – 3
Cohort Mortality/Hospice p-value*
No anticoagulant, N (%)         64 (3.7%)
Antiplatelet, N (%)         67 (4.5%)
DOAC alone, N (%)         12 (8.6%)
Warfarin alone, N (%)         29 (7.4%)
<0.001
AIS Head – 4
Cohort Mortality/Hospice p-value*
No anticoagulant, N (%)         81 (7.1%)
Antiplatelet, N (%)         58 (5.4%)
DOAC alone, N (%)           8 (9.1%)
Warfarin alone, N (%)         30 (11.5%)
<0.001
AIS Head – 5
Cohort Mortality/Hospice p-value*
No anticoagulant, N (%)       229 (30.5%)
Antiplatelet, N (%)       221 (30.5%)
DOAC alone, N (%)         28 (36.4%)
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Table 3. Unadjusted Study Outcomes
Abbreviations: DOAC, direct oral anticoagulant; LOS, length of stay; ICU, intensive care unit 
No anticoagulant Antiplatelet DOAC alone Warfarin alone p value
Serious Complications, N (%)        243 (6.7)     270 (8.2)      13 (6.9)     79 (11.8) <0.001
Surgery, N (%)        579 (16.6)     498 (15.3)      34 (18.1)   141 (21.6)    0.002
Hospital LOS, days ± SD 5.6 ± 5.7 5.6 ± 5.9 5.2 ± 4.6 6.7 ± 7.4 <0.001
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Figure 1 Legend:
Abbreviations: TBI, traumatic brain injury; DOAC, direct oral anticoagulant.
Figure 2 Legend:














































Total  DOAC   304 
  DOAC          188 
  DOAC+AP   116 
3293 
Antiplatelet agents 
Total Warfarin  1083 
  Warfarin           669 

















Figure 2. Mortality or Hospice
 









No Anticoagulant Warfarin DOAC Warfarin + AP DOAC + AP
Hospice
Mortality
Reference 1.60
(1.27 – 2.01)
1.61
(1.18 – 2.21)
0.93
(0.46 – 1.87)
1.67
(1.07 – 2.59)
 
AOR 
(95% CI) 
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